Security key
005329107
Adagene Inc. - Ordinary shares, par value USD $0.0001 per share (ADAG)
CUSIP: 005329107
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Ordinary shares, par value USD $0.0001 per share
- Total 13F shares
- 3,089,667
- Total 13F value
- $6,027,495
- Share change
- -2,672,764
- SEC-reported price per share
- $1.89
- Number of holders
- 17
- Value change
- -$5,437,806
- Number of buys
- 6
- Number of sells
- 7
- Shares outstanding
- 83,843,205
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
17
Top holders
10
ADAG full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Adagene Inc. SEC filings
Adagene Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 005329107
Recent filing periods:
Ownership snapshot
Top reported holders of ADAG - Adagene Inc. - Ordinary shares, par value USD $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Vincent C. Smith
Disclosed value leader
Vincent C. Smith
Comparable rows
15/15
Latest evidence
31 Dec 2025
13D/G
13F
Lead comparable stake: 8.7%
13D/G row: Vincent C. Smith
Showing 1-6 of 15 holder rows.
Quick read
Vincent C. Smith leads the comparable SEC ownership view at 8.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Vincent C. Smith's linked filing trail.
Comparable ownership
Top 5
Vincent C. Smith
8.7%
WuXi PharmaTech Healthcare Fund I...
7%
Panacea Innovation Ltd
3.8%
FIL Ltd
1.8%
FMR LLC
0.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vincent C. Smith |
13D/G
Smith Vincent C
|
8.7%
|
$9,120,679
5,095,351 shares
|
+$2,258,166 | 31 Dec 2025 |
| WuXi PharmaTech Healthcare Fund I L.P. |
13D/G
|
7%
|
$8,187,161
4,121,815 shares
|
-$1,701,888 | 30 Sep 2025 |
| Panacea Innovation Ltd |
13D/G
Panacea Venture Healthcare Fund II, L.P.
|
3.8%
|
$4,469,175
2,250,000 shares
|
-$1,564,211 | 30 Sep 2025 |
| FIL Ltd |
13D/G
FIL Limited
|
1.8%
|
$1,320,902
936,810 shares
|
-$4,450,930 | 31 Mar 2025 |
| FMR LLC |
13D/G
|
0.9%
|
$933,679
473,949 shares
|
$0 | 30 Jun 2025 |
| GENERAL ATLANTIC, L.P. |
13F
Company
|
4.5%
|
$7,526,855
3,782,339 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
17
Shares
3,089,667
Rows available
17
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
17
Q4 2025 holders
17
Holder diff
0
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend